ZK200775 + ZK200775 + Sodium Chloride
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Visual Acuity
Conditions
Visual Acuity
Trial Timeline
Dec 1, 1996 → Apr 1, 1998
NCT ID
NCT00999284About ZK200775 + ZK200775 + Sodium Chloride
ZK200775 + ZK200775 + Sodium Chloride is a phase 1 stage product being developed by Bayer for Visual Acuity. The current trial status is completed. This product is registered under clinical trial identifier NCT00999284. Target conditions include Visual Acuity.
What happened to similar drugs?
3 of 9 similar drugs in Visual Acuity were approved
Approved (3) Terminated (3) Active (5)
Hype Score Breakdown
Clinical
6
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00999284 | Phase 1 | Completed |
Competing Products
13 competing products in Visual Acuity
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| pudexacianinium chloride | Astellas Pharma | Phase 3 | 40 |
| Blink® Tears eye drops + Investigational lipid eye drops | Johnson & Johnson | Phase 1 | 29 |
| Blink® Tears eye drops in a multidose bottle + Preservative-free investigational lubricating eye drops in a Novelia® eyedropper | Johnson & Johnson | Phase 2 | 35 |
| Ranibizumab | Novartis | Phase 3 | 40 |
| Ranibizumab + Aflibercept | Novartis | Approved | 35 |
| Ranibizumab | Novartis | Approved | 43 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 40 |
| Sham injections + Ranibizumab 0.5 mg | Novartis | Phase 3 | 32 |
| Ranibizumab + Dexamethasone implant and sham injections | Novartis | Phase 3 | 40 |
| Ranibizumab + Aflibercept | Novartis | Approved | 35 |
| Intravitreal Lucentis 0.5mg | Novartis | Pre-clinical | 22 |
| Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 27 |